Bristol-Myers Squibb Revenue 2006-2018 | BMY

Current and historical revenue for Bristol-Myers Squibb (BMY) from 2006 to 2018. The sum of all revenue fields included for a company's operating activities. The current revenue for Bristol-Myers Squibb as of March 31, 2018 is .
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $94.148B $20.776B
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $346.390B 16.55
Pfizer (PFE) United States $224.125B 13.79
Novartis AG (NVS) Switzerland $182.384B 15.80
Merck (MRK) United States $168.593B 15.07
AbbVie (ABBV) United States $151.404B 15.44
Novo Nordisk (NVO) Denmark $122.519B 20.30
Sanofi (SNY) France $105.189B 13.31
GlaxoSmithKline (GSK) United Kingdom $102.004B 13.95
Eli Lilly (LLY) United States $97.222B 19.30
AstraZeneca (AZN) United Kingdom $94.148B 9.86